Core Viewpoint - Kunming Pharmaceutical Group has undergone a significant leadership change, with a complete overhaul of its core decision-making and operational teams, aiming to address recent performance challenges and adapt to external market pressures [1][2][3][4] Leadership Changes - Yu Xiang has been appointed as the new chairman, with a term lasting until January 22, 2028, succeeding Wu Wendo, who will remain on the board [1] - The new president, Zhong Jiang, has been appointed alongside Yu Xiang, with both leaders coming from the China Resources system, indicating a strategic shift in management [2][3] - Former president Yan Wei will transition to the role of vice chairman and board member, while former vice president Li Lichun will no longer hold any positions within the company [2] Financial Performance - Kunming Pharmaceutical Group has faced significant financial pressure, with a reported revenue of 4.751 billion yuan for the first three quarters of 2025, marking an 18.08% year-on-year decline [3] - The net profit attributable to shareholders decreased by 39.42% to 269 million yuan, while the net profit after deducting non-recurring items fell by 59.52% [3] - The company's accounts receivable have increased dramatically, rising from 1.358 billion yuan in mid-2020 to 3.25 billion yuan in mid-2025, a cumulative increase of 139.32% [3] Business Challenges - The primary revenue source, the Xuesaitong series, which accounts for approximately 40% of total revenue, is under pressure from price suppression due to centralized procurement policies, despite showing signs of recovery [4] - The premium traditional Chinese medicine segment, making up about 30% of revenue, is currently undergoing brand upgrades and channel restructuring, lacking stable growth momentum [4] - The new leadership team is expected to integrate resources and implement strategies to gradually restore the company's performance amidst these challenges [4]

Group 1 - Lichong Group expects a net profit of 830 million to 870 million yuan for 2025, representing a year-on-year growth of 17.38% to 23.04% [1] - Shandong Zhanggu anticipates a net profit of 72 million to 80 million yuan for 2025, with a year-on-year increase of 0.65% to 11.83% [2] - Yinglian Co. forecasts a net profit of 32 million to 42 million yuan for 2025, marking a turnaround from a loss of 39.67 million yuan in the previous year [3] Group 2 - Hangya Technology announces plans for shareholders to reduce their holdings by up to 2.76% of the company's shares [4] - Guizhou Tire plans to invest in a project in Morocco to produce 6 million semi-steel radial tires annually, with a total investment of 299 million USD [5] - Laisentongling's shareholder plans to reduce their stake by no more than 1% [6] Group 3 - ST Yifei's shareholder intends to reduce their holdings by up to 1.53% [7] - Hengyi Petrochemical has fully launched the second phase of its Brunei refining project, aiming for a production capacity of 12 million tons per year [8] - Zai Sheng Technology's controlling shareholder has terminated an agreement to transfer part of the company's shares [9] Group 4 - Sry New Materials proposes a cash dividend of 0.4 yuan per 10 shares for the first three quarters of 2025 [10] - Quanyin High-Tech announces that the offer period for China Seed Group's acquisition has expired, leading to a temporary suspension of its stock [11] - Zhonggang Luonai's shareholder plans to reduce their stake by up to 1% [12] Group 5 - Nanmo Bio expects to receive a government subsidy of 5.8 million yuan for its subsidiary [13] - Beite Technology has received approval from the China Securities Regulatory Commission for a stock issuance to specific investors [14] - Qianyuan Pharmaceutical's subsidiary has obtained drug registration certificates for a new medication [15] Group 6 - Boto Integrated plans to reduce its holdings by no more than 1% [16] - Wanze Co. intends to reduce its stake by up to 1.66% [17] - Tianci Materials will halt production for maintenance on its lithium hexafluorophosphate production line starting March 1, 2026 [18] Group 7 - Haopeng Technology plans to raise up to 800 million yuan through a private placement [20] - Yisheng Co. reports a 43.32% year-on-year increase in sales revenue for its white feather broiler chicks in December 2025 [21] - Jinyu Medical proposes a cash dividend of 8.8 yuan per 10 shares for the first three quarters of 2025 [22] Group 8 - Caesar Travel's subsidiary has won a management service project for the Qingdao International Cruise Port [23] - Kelun Pharmaceutical plans to repurchase shares worth 50 million to 100 million yuan [24] - Jiangling Motors reports a 10.56% year-on-year increase in cumulative sales for 2025 [25] Group 9 - Yilian Technology plans to issue convertible bonds to raise up to 1.2 billion yuan [26] - Shaanxi Guotou A intends to participate in a capital increase for Chang'an Bank, with an amount not exceeding 800 million yuan [27] - Oupokang Vision has obtained a production license for eye drops [28] Group 10 - Shanghai Electric plans to provide management services for overseas assets of China Electric International [30] - Yingfang Micro is planning a major asset restructuring, leading to a temporary suspension of its stock [31] - Victory Energy's stock will resume trading after completing a verification process [32] Group 11 - China Merchants Industry has signed a shipbuilding agreement with Dalian Shipbuilding [33] - Kunyu Group has appointed a new chairman following a board meeting [34] - Microchip Bio's clinical trial application for a new diabetes treatment has been accepted [35] Group 12 - Hanshuo Technology has signed a sales intention agreement for smart shopping carts with Woolworths in Australia [36] - Zhongmin Energy's three photovoltaic power station projects have been included in the Fujian Province development list [37] - Penghui Energy plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [38] Group 13 - Victory Energy reports that the acquirer has deposited a guarantee for the acquisition [39] - Fangsheng Pharmaceutical proposes a special dividend of 0.15 yuan per share for 2025 [40] - Nanning Department Store has received approximately 14.28 million yuan in government subsidies since January 2025 [41] Group 14 - Jushen Co. has signed a bauxite transfer agreement with a company in Guinea [42] - ST Huluwawa has received a drug registration certificate for a new inhalation solution [43] - Zhongzhi Co. will become the controlling shareholder following a share transfer agreement [44] Group 15 - Chuangli Group has signed a strategic cooperation framework agreement with Chuanjiu Construction [45]

证券代码：600422 证券简称：昆药集团 公告编号：2026-003号 昆药集团股份有限公司 因工作调动原因，颜炜先生不再担任昆药集团股份有限公司（以下简称"公司"）总裁职务，继续担任公 司副董事长、董事及董事会战略与ESG委员会委员；李立春先生不再担任公司副总裁职务。 根据公司发展及生产经营管理的需要，公司董事会聘任钟江先生为公司总裁，任期自公司董事会审议通 过之日起至十一届董事会届满之日止。 一、高级管理人员离任情况 （一）提前离任的基本情况 ■ （二）离任对公司的影响 颜炜先生、李立春先生已按照公司相关规定做好交接工作，其工作调动不会影响公司董事会正常运作和 公司的生产经营管理。截至本公告日，颜炜先生、李立春先生未持有公司股票，不存在应当履行而未履 行的承诺事项。 颜炜先生在担任公司总裁期间，恪尽职守、勤勉尽责，在推动公司向"银发健康产业引领者"战略目标迈 进的进程中发挥了重大作用，为公司的长期可持续发展作出了重大贡献。公司董事会谨对颜炜先生在任 职期间对公司发展作出的重大贡献表示衷心感谢！ 关于高级管理人员变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 ...

经公司董事会会议审议通过，推举非独立董事喻翔为公司十一届董事会董事长，任期自公司董事会审议 通过之日起至十一届董事会届满之日止。 北京商报讯（记者 王寅浩 宋雨盈）1月5日，昆药集团发布公告称，因工作调整原因，吴文多不再担任 公司董事长职务，继续担任公司董事、董事会战略与ESG委员会委员、董事会提名委员会委员。 ...

北京商报讯（记者 王寅浩 宋雨盈）1月5日，昆药集团发布公告称，因工作调动原因，颜炜不再担任公 司总裁职务，继续担任公司副董事长、董事及董事会战略与ESG委员会委员；李立春不再担任公司副总 裁职务。 同时，公司董事会聘任钟江为公司总裁，任期自公司董事会审议通过之日起至十一届董事会届满之日 止。 ...

人民财讯1月5日电，昆药集团（600422）1月5日公告，因工作调整原因，吴文多不再担任昆药集团股份 有限公司董事长职务，继续担任公司董事、董事会战略与ESG委员会委员、董事会提名委员会委员。经 公司十一届十四次董事会会议审议通过，推举非独立董事喻翔为公司十一届董事会董事长，任期自公司 董事会审议通过之日起至十一届董事会届满之日止。 ...

每经AI快讯，昆药集团1月5日晚间发布公告称，因工作调整原因，吴文多先生不再担任昆药集团股份 有限公司(以下简称"公 司")董事长职务，继续担任公司董事、董事会战略与ESG委员会委员、董事会 提 名委员会委员。 经公司十一届十四次董事会会议审议通过，推举非独立董事喻翔先生为公司十一届董事会董事长，任期 自公司董事会审议通过之日起至十一届董事会届满之 日止。 每经头条（nbdtoutiao）——秒光！1499元飞天茅台上线即空，i茅台App冲上苹果购物榜第一，10万用 户已下单！经销商同价做回馈，1000箱很快卖完 （记者 王晓波） ...

证券代码：600422 证券简称：昆药集团 公告编号：2026-003号 昆药集团股份有限公司 关于高级管理人员变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 因工作调动原因，颜炜先生不再担任昆药集团股份有限公司（以下简称"公 司"）总裁职务，继续担任公司副董事长、董事及董事会战略与 ESG 委员会委员； 李立春先生不再担任公司副总裁职务。 根据公司发展及生产经营管理的需要，公司董事会聘任钟江先生为公司总裁， 任期自公司董事会审议通过之日起至十一届董事会届满之日止。 一、高级管理人员离任情况 （一）提前离任的基本情况 | | | | | | 是否继续在 | | 是否存在 | | --- | --- | --- | --- | --- | --- | --- | --- | | 姓名 | 离任职务 | 离任时间 | 原定任期 | 离任原因 | 上市公司及 | 具体职务（如 | 未履行完 | | | | | 到期日 | | 其控股子公 | 适用） | 毕的公开 | | | | | | | 司任职 | | ...

证券代码：600422 证券简称：昆药集团 公告编号：2026-002号 昆药集团股份有限公司关于董事长变更的公告 重要内容提示： 因工作调整原因，吴文多先生不再担任昆药集团股份有限公司（以下简称"公 司"）董事长职务，继续担任公司董事、董事会战略与 ESG 委员会委员、董事会 提名委员会委员。 经公司十一届十四次董事会会议审议通过，推举非独立董事喻翔先生为公司 十一届董事会董事长，任期自公司董事会审议通过之日起至十一届董事会届满之 日止。 一、董事长离任情况 （一）提前离任的基本情况 | | 离任职 | | 原定任期 | | 是否继续 在上市公 | | 是否存在 未履行完 | | --- | --- | --- | --- | --- | --- | --- | --- | | 姓名 | 务 | 离任时间 | 到期日 | 离任原因 | 司及其控 | 具体职务（如适用） | 毕的公开 | | | | | | | 股子公司 | | 承诺 | | | | | | | 任职 | | | | 吴文多 | 董事长 | 2026.1.4 | 2028.1.22 | 工作调整 | 是 | 董事、董事会战略 与 委员会委 E ...

证券代码：600422 证券简称：昆药集团 公告编号：2026-001号 昆药集团股份有限公司十一届十四次董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 昆药集团股份有限公司（以下简称"公司"）十一届十四次董事会会议通知和材 料以书面方式于 2026 年 1 月 4 日发出，于 2026 年 1 月 5 日以现场结合线上会议的方 式在公司会议室召开。经全体董事一致同意豁免会议通知时限。会议由吴文多先生召 集并主持，本次会议应参加表决董事 15人，实际参加表决 15 人，符合《公司法》和 《公司章程》的规定。会议以记名方式投票表决，审议并通过以下决议： 1、 关于选举公司十一届董事会董事长的议案（详见《昆药集团关于董事长变更的公 告》） 同意：15 票 反对：0 票 弃权：0 票 本议案已经公司十一届董事会提名委员会 2026 年第一次会议审议通过，并同意 提交公司董事会审议。 同意：15 票 反对：0 票 弃权：0 票 特此公告。 昆药集团股份有限公司董事会 2026 年 1 月 6 日 1 2、关于聘任公司总 ...